



Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in Health and Disease

Guest Editor:

Dr. Sylvain Broussy

Faculty of Pharmacy, Université
Paris Cité, Paris, France

Deadline for manuscript
submissions:

closed (23 December 2023)

Message from the Guest Editor

Dear Colleagues,

Vascular endothelial growth factors (VEGF-A/B/C/D and placental growth factor (PlGF)) and their receptors (VEGFRs) and co-receptor neuropilins (NRP) are the main pro-angiogenic and lymphangiogenic factors in mammals. Pharmaceuticals targeting the VEGF/VEGFR axis have been successfully used to treat several cancers and ocular diseases but have shown some limitations, in particular regarding their long-term efficiency and their route of administration. Interestingly, recent research has expanded to smaller molecular entities with designed properties. Moreover, new formulations and composition of matters are now developed to improve the delivery of inhibitors. The conjugation of VEGF/VEGFR inhibitors with other molecular entities for specific targeting and for combination therapy is also a promising new strategy.

In this Special Issue, we aim to present significant research results in the field of VEGF/VEGFR inhibition that highlight the most recent strategies and promising therapeutic molecules. These studies will help to anticipate and shape the future therapeutic opportunities provided by an efficient modulation of this key axis in angiogenesis.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com